Merck & Co Inc (MRK)
127.00
+0.12
(+0.09%)
USD |
NYSE |
Apr 24, 16:00
126.94
-0.06
(-0.05%)
After-Hours: 20:00
Merck Research and Development Expense (Quarterly): 9.627B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.627B |
| September 30, 2023 | 3.307B |
| June 30, 2023 | 13.32B |
| March 31, 2023 | 4.276B |
| December 31, 2022 | 3.775B |
| September 30, 2022 | 4.399B |
| June 30, 2022 | 2.798B |
| March 31, 2022 | 2.576B |
| December 31, 2021 | 3.068B |
| September 30, 2021 | 2.445B |
| June 30, 2021 | 4.321B |
| March 31, 2021 | 2.412B |
| December 31, 2020 | 5.788B |
| September 30, 2020 | 3.349B |
| June 30, 2020 | 2.085B |
| March 31, 2020 | 2.209B |
| December 31, 2019 | 2.40B |
| September 30, 2019 | 3.204B |
| June 30, 2019 | 2.189B |
| March 31, 2019 | 1.931B |
| December 31, 2018 | 2.214B |
| September 30, 2018 | 2.068B |
| June 30, 2018 | 2.274B |
| March 31, 2018 | 3.196B |
| December 31, 2017 | 2.315B |
| Date | Value |
|---|---|
| September 30, 2017 | 4.413B |
| June 30, 2017 | 1.782B |
| March 31, 2017 | 1.83B |
| December 31, 2016 | 4.786B |
| September 30, 2016 | 1.664B |
| June 30, 2016 | 2.151B |
| March 31, 2016 | 1.659B |
| December 31, 2015 | 1.798B |
| September 30, 2015 | 1.50B |
| June 30, 2015 | 1.67B |
| March 31, 2015 | 1.737B |
| December 31, 2014 | 2.283B |
| September 30, 2014 | 1.659B |
| June 30, 2014 | 1.664B |
| March 31, 2014 | 1.574B |
| December 31, 2013 | 1.835B |
| September 30, 2013 | 1.66B |
| June 30, 2013 | 2.101B |
| March 31, 2013 | 1.907B |
| December 31, 2012 | 2.224B |
| September 30, 2012 | 1.918B |
| June 30, 2012 | 2.165B |
| March 31, 2012 | 1.862B |
| December 31, 2011 | 2.419B |
| September 30, 2011 | 1.954B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.085B
Minimum
Jun 2020
13.32B
Maximum
Jun 2023
4.082B
Average
3.204B
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.534B |
| Johnson & Johnson | 3.542B |
| Eli Lilly and Co | 2.563B |
| Pfizer Inc | 2.815B |
| Moderna Inc | 1.406B |